6 hours ago
CBF president Samir Xaud visited Pedro Pedrossian Stadium, known as Morenão, in Campo Grande on the morning of this Wednesday (2), on the eve of the inauguration of the Football Development Center of the State of Mato Grosso do Sul. Opened in 1971 and with a capacity of more than 40,000 fans, the main stage of football in Mato Grosso do Sul is receiving an investment of around R$ 1 million from the CBF to revitalize the pitch.
Xaud was accompanied by the president of the Mato Grosso do Sul Football Federation (FFMS), Estevâo Petrallás, who presented the stadium's history and detailed the progress of the work, as well as the president of the Mato Grosso Football Federation (FMF), Diogo Pécora, and the State Secretary of Tourism, Sports and Culture (Setesc), Alessandro Menezes.
CBF president Samir Xaud visited Morenão Stadium, which is receiving CBF investment to revitalize the pitchCredits: Rodrigo Moreira/CBF
In an interview with CBF TV, the CBF president commented on the importance of the institutional agenda in Mato Grosso do Sul and praised the history and renovation work at Morenão. The stadium has also hosted Brazil national team matches: a 1-1 draw with Paraguay on February 27, 1991, in a friendly; and a goalless draw with Venezuela on October 14, 2009, in the qualifiers for the 2010 World Cup.
"Today we began our institutional visit to Mato Grosso do Sul, continuing our work toward more participatory management and closer ties with the federations. We are here at Morenão, a stadium with a history shared by the entire state population, and where the CBF has provided funds to help revitalize the stadium, including replacing the pitch, irrigation and drainage. For us, it is another joy to work to help Brazilian football as a whole and the smaller federations," he said.
#mato #xaud #work #state
Xaud was accompanied by the president of the Mato Grosso do Sul Football Federation (FFMS), Estevâo Petrallás, who presented the stadium's history and detailed the progress of the work, as well as the president of the Mato Grosso Football Federation (FMF), Diogo Pécora, and the State Secretary of Tourism, Sports and Culture (Setesc), Alessandro Menezes.
CBF president Samir Xaud visited Morenão Stadium, which is receiving CBF investment to revitalize the pitchCredits: Rodrigo Moreira/CBF
In an interview with CBF TV, the CBF president commented on the importance of the institutional agenda in Mato Grosso do Sul and praised the history and renovation work at Morenão. The stadium has also hosted Brazil national team matches: a 1-1 draw with Paraguay on February 27, 1991, in a friendly; and a goalless draw with Venezuela on October 14, 2009, in the qualifiers for the 2010 World Cup.
"Today we began our institutional visit to Mato Grosso do Sul, continuing our work toward more participatory management and closer ties with the federations. We are here at Morenão, a stadium with a history shared by the entire state population, and where the CBF has provided funds to help revitalize the stadium, including replacing the pitch, irrigation and drainage. For us, it is another joy to work to help Brazilian football as a whole and the smaller federations," he said.
#mato #xaud #work #state
22 hours ago
Ross Stewart looks set to miss Swansea City's next four matches because of a quad injury.
Scotland striker Stewart missed the Swans' Championship victory over Watford on Tuesday as well last Saturday's win at Derby County.
The 30-year-old has made only one substitute appearance, in the goalless draw with Sheffield United 11 days ago, since joining Swansea on a three-year contract last month.
Stewart is now expected to miss Swansea's home game against Wrexham on Saturday as well as the trip to Southampton – his former club – next Tuesday and fixtures against Burnley and Lincoln City prior to the international break at the end of the month.
"Ross had a soft tissue injury, not massive, but probably he can return in the international break," said Swansea head coach Vitor Matos.
#ross
Scotland striker Stewart missed the Swans' Championship victory over Watford on Tuesday as well last Saturday's win at Derby County.
The 30-year-old has made only one substitute appearance, in the goalless draw with Sheffield United 11 days ago, since joining Swansea on a three-year contract last month.
Stewart is now expected to miss Swansea's home game against Wrexham on Saturday as well as the trip to Southampton – his former club – next Tuesday and fixtures against Burnley and Lincoln City prior to the international break at the end of the month.
"Ross had a soft tissue injury, not massive, but probably he can return in the international break," said Swansea head coach Vitor Matos.
#ross
5 days ago
Swansea head coach Vitor Matos is "really pleased" with their unbeaten start to the Championship season, but insisted they still have small improvements to make.
Goals from Joseph Opoku, Eom Ji-sung and Ronald gave Swansea a 3-0 win at Derby, taking Matos' charges to seven points from three games - their best start to a season since 2020-21.
The Swans won just seven of their 23 away Championship fixtures last season, but have taken six points from six at the start of this campaign.
Matos, into his second campaign in charge of Swansea, is pleased with their improved record on the road, and feels his players are enjoying themselves.
"There is still a lot to play [this season], but we are really pleased that we did a good job for our fans who were here," said Matos.
#season #pleased #championship #still
Goals from Joseph Opoku, Eom Ji-sung and Ronald gave Swansea a 3-0 win at Derby, taking Matos' charges to seven points from three games - their best start to a season since 2020-21.
The Swans won just seven of their 23 away Championship fixtures last season, but have taken six points from six at the start of this campaign.
Matos, into his second campaign in charge of Swansea, is pleased with their improved record on the road, and feels his players are enjoying themselves.
"There is still a lot to play [this season], but we are really pleased that we did a good job for our fans who were here," said Matos.
#season #pleased #championship #still
6 days ago
Al Michaels has reached a remarkable number of milestones, and Thursday night marked his crowning achievement. And it didn't have to do with his work as a legendary play-by-play announcer.
Michaels and his wife, Linda Anne Stamato, celebrated their 60th wedding anniversary on Thursday.
Thursday also brought the first Amazon Prime Video NFL broadcast of the 2026 football season, with the New England Patriots taking on the Cleveland Browns.
So, Michaels had play-by-play duties for Prime Video at Huntington Bank Field, and the Browns wished Al and Linda a happy 60th anniversary on the videoboard.
And with the second half about to start, Cleveland first-year head coach Todd Monken spoke with Prime Video sideline reporter Kaylee Hartung, who asked him about Browns quarterback Dillon Gabriel. Unprompted, Monken used the interview as an opportunity to deliver a message to Al and Linda.
#anniversary
Michaels and his wife, Linda Anne Stamato, celebrated their 60th wedding anniversary on Thursday.
Thursday also brought the first Amazon Prime Video NFL broadcast of the 2026 football season, with the New England Patriots taking on the Cleveland Browns.
So, Michaels had play-by-play duties for Prime Video at Huntington Bank Field, and the Browns wished Al and Linda a happy 60th anniversary on the videoboard.
And with the second half about to start, Cleveland first-year head coach Todd Monken spoke with Prime Video sideline reporter Kaylee Hartung, who asked him about Browns quarterback Dillon Gabriel. Unprompted, Monken used the interview as an opportunity to deliver a message to Al and Linda.
#anniversary
6 days ago
Spyre Therapeutics (SYRE) took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.
But **** ysts are far more interested in Spyre's inflammatory bowel disease drugs. These conditions include ulcerative colitis and Crohn's disease.
"Even excluding all non-UC (ulcerative colitis) indications, our PT (price target) would remain at ~$115, well above current trading levels," Wedbush **** yst David Nierengarten said in a client note. "While we view the RS (rheumatoid arthritis) results as disappointing, we see limited impact to our core IBD-driven (inflammatory bowel disease) thesis."
Still, Spyre stock fell 1.8%, closing at 93.61. Shares are highly rated with a strong IBD Digital Relative Strength Rating of 98, putting the stock's 12-month performance in the leading 2% of all stocks.
Spyre's drug, dubbed SPY072, actually showed some effectiveness in patients with rheumatoid arthritis. But the results didn't pass the company's internal bar for advancement. Spyre is still testing SPY072 in other rheumatology indications, including psoriatic arthritis and axial spondyloarthritis.
#arthritis #testing #bowel
But **** ysts are far more interested in Spyre's inflammatory bowel disease drugs. These conditions include ulcerative colitis and Crohn's disease.
"Even excluding all non-UC (ulcerative colitis) indications, our PT (price target) would remain at ~$115, well above current trading levels," Wedbush **** yst David Nierengarten said in a client note. "While we view the RS (rheumatoid arthritis) results as disappointing, we see limited impact to our core IBD-driven (inflammatory bowel disease) thesis."
Still, Spyre stock fell 1.8%, closing at 93.61. Shares are highly rated with a strong IBD Digital Relative Strength Rating of 98, putting the stock's 12-month performance in the leading 2% of all stocks.
Spyre's drug, dubbed SPY072, actually showed some effectiveness in patients with rheumatoid arthritis. But the results didn't pass the company's internal bar for advancement. Spyre is still testing SPY072 in other rheumatology indications, including psoriatic arthritis and axial spondyloarthritis.
#arthritis #testing #bowel
6 days ago
Conservatives piled on Democratic Rep. Debbie Dingell after she argued Republicans are trying to make Michigan's Senate race about socialist streamer Hasan Piker, with critics saying her frustration only highlighted a political vulnerability for Democrats.
"Debbie Dingell CRASHES OUT over terrorist-sympathizer Hasan Piker who has called to kill Republicans,'" wrote the Republican National Committee's research account.
Critics took aim at Dingell for campaigning with Michigan Democratic Senate candidate Abdul El-Sayed after she told reporters she was done answering questions about Piker, whose past inflammatory remarks have drawn renewed scrutiny and pressure on Democrats to respond.
Democrats Condemning Hasan Piker As Backlash Spreads Through Party
"YIKES: Democrats are getting tired of defending Abdul El-Sayed for his antisemitic campaign surrogate Hasan Piker Rep. Debbie Dingell: 'I am DONE. So don't any reporter ask me again about Hasan Piker.' El-Sayed has yet to disavow Piker," wrote Senate Republicans on X.
#dingell #senate
"Debbie Dingell CRASHES OUT over terrorist-sympathizer Hasan Piker who has called to kill Republicans,'" wrote the Republican National Committee's research account.
Critics took aim at Dingell for campaigning with Michigan Democratic Senate candidate Abdul El-Sayed after she told reporters she was done answering questions about Piker, whose past inflammatory remarks have drawn renewed scrutiny and pressure on Democrats to respond.
Democrats Condemning Hasan Piker As Backlash Spreads Through Party
"YIKES: Democrats are getting tired of defending Abdul El-Sayed for his antisemitic campaign surrogate Hasan Piker Rep. Debbie Dingell: 'I am DONE. So don't any reporter ask me again about Hasan Piker.' El-Sayed has yet to disavow Piker," wrote Senate Republicans on X.
#dingell #senate
7 days ago
On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 trials for two separate autoimmune conditions, atopic dermatitis and alopecia areata. Management framed the quarter around two numbers that matter most to investors right now: a $1.02 billion cash balance that provides a runway into 2028, and a drug program that finally has late-stage data on the calendar.
Nektar's Phase 3 program for atopic dermatitis, called ZENITH AD, began randomizing patients in July 2026 across two pivotal studies, each enrolling 510 adolescent and adult patients. A third study in patients who have already tried other treatments is set to start by the end of September 2026. Management expects top-line data from the first studies in mid-2028, with a Biologics License Application submission to follow in 2029 if results hold up. After an end-of-Phase 2 meeting with the FDA, Nektar also finalized a single registrational Phase 3 study for alopecia areata, called ZENITH AA, which will enroll 850 patients and use a SALT score of 20 or less at week 52, meaning 80% or more scalp hair coverage, as its primary endpoint.
The case for rezpeg goes beyond trial design. CEO Howard Robin noted that roughly 15 million people in the U.S. have moderate to severe atopic dermatitis, and fewer than 10% currently get a systemic therapy, leaving room for the market itself to grow. He also pointed out that about half of patients on IL-13 drugs such as Dupixent either stop responding or never respond at all. In alopecia areata, where JAK inhibitors carry boxed warnings that keep many dermatologists away, the market for approved treatments is still projected to reach $5 billion by 2033. Nektar's own market research found that 150 of 151 physicians surveyed preferred rezpeg's short-lived injection site reactions over the longer-lasting conjunctivitis tied to current options, a result management used to argue rezpeg could compete across first, second, and third-line patients.
None of this comes cheap. Nektar's operating loss widened to $42.3 million in the second quarter, up from $36.2 million a year earlier, and the net loss came in at $40.6 million, or $1.23 per share. Research and development spending is set to climb further, with full-year guidance now at $210 million to $230 million as the Phase 3 programs and manufacturing activities ramp up. The company's only revenue right now is $10.1 million in noncash royalty income, down from $11.2 million a year ago, and full-year revenue guidance tops out at $45 million. That gap between spending and revenue is why Nektar leaned on a public stock offering that raised $373.8 million in gross proceeds in April 2026, a move that keeps the lights on but also dilutes existing shareholders.
#quarter
Nektar's Phase 3 program for atopic dermatitis, called ZENITH AD, began randomizing patients in July 2026 across two pivotal studies, each enrolling 510 adolescent and adult patients. A third study in patients who have already tried other treatments is set to start by the end of September 2026. Management expects top-line data from the first studies in mid-2028, with a Biologics License Application submission to follow in 2029 if results hold up. After an end-of-Phase 2 meeting with the FDA, Nektar also finalized a single registrational Phase 3 study for alopecia areata, called ZENITH AA, which will enroll 850 patients and use a SALT score of 20 or less at week 52, meaning 80% or more scalp hair coverage, as its primary endpoint.
The case for rezpeg goes beyond trial design. CEO Howard Robin noted that roughly 15 million people in the U.S. have moderate to severe atopic dermatitis, and fewer than 10% currently get a systemic therapy, leaving room for the market itself to grow. He also pointed out that about half of patients on IL-13 drugs such as Dupixent either stop responding or never respond at all. In alopecia areata, where JAK inhibitors carry boxed warnings that keep many dermatologists away, the market for approved treatments is still projected to reach $5 billion by 2033. Nektar's own market research found that 150 of 151 physicians surveyed preferred rezpeg's short-lived injection site reactions over the longer-lasting conjunctivitis tied to current options, a result management used to argue rezpeg could compete across first, second, and third-line patients.
None of this comes cheap. Nektar's operating loss widened to $42.3 million in the second quarter, up from $36.2 million a year earlier, and the net loss came in at $40.6 million, or $1.23 per share. Research and development spending is set to climb further, with full-year guidance now at $210 million to $230 million as the Phase 3 programs and manufacturing activities ramp up. The company's only revenue right now is $10.1 million in noncash royalty income, down from $11.2 million a year ago, and full-year revenue guidance tops out at $45 million. That gap between spending and revenue is why Nektar leaned on a public stock offering that raised $373.8 million in gross proceeds in April 2026, a move that keeps the lights on but also dilutes existing shareholders.
#quarter
7 days ago
Stockard Channing, 82, made her first red carpet appearance in two years on Wednesday, just days after admitting she's become a "recluse" since the death of her partner in 2014.
The 82-year-old actor attended the European premiere of Practical Magic 2 at Odeon Luxe Leicester Square in London on Wednesday. She reprises her role as Frances "Fran" Owens, the witch aunt of Sally Owens (played by Sandra Bullock) and Gillian Owens (played by Nicole Kidman) in the fantasy sequel.
It was her first time back on the red carpet since a low-key appearance at the press night for **** o, Dolly! at the London Palladium in July 2024.
It comes after Channing told The Sunday Times about her move to London from Maine following the death of her partner, cinematographer Daniel Gillham, in 2014. The couple had been together for 24 years after meeting on the set of World War II drama A Time of Destiny.
"I've lived alone since I lost Daniel and I'm happy being a recluse," she said.
#since
The 82-year-old actor attended the European premiere of Practical Magic 2 at Odeon Luxe Leicester Square in London on Wednesday. She reprises her role as Frances "Fran" Owens, the witch aunt of Sally Owens (played by Sandra Bullock) and Gillian Owens (played by Nicole Kidman) in the fantasy sequel.
It was her first time back on the red carpet since a low-key appearance at the press night for **** o, Dolly! at the London Palladium in July 2024.
It comes after Channing told The Sunday Times about her move to London from Maine following the death of her partner, cinematographer Daniel Gillham, in 2014. The couple had been together for 24 years after meeting on the set of World War II drama A Time of Destiny.
"I've lived alone since I lost Daniel and I'm happy being a recluse," she said.
#since
8 days ago
Hyundai Department Store is preparing to launch COOD, which it describes as South Korea's first speciality select shop built around derma beauty as its core concept.
According to a translated version of the Yonhap News Agency report, the inaugural outlet will open on the basement level of the company's Pangyo store on 18 September.
Spanning approximately 165.28m², the store will stock more than 60 derma beauty brands.
Derma beauty, a term combining "dermatology" and "beauty", describes products created through research and development involving input from medical and bio-science specialists, aimed at enhancing skin function.
Hyundai Department Store noted that although derma beauty items have already been sold within established beauty retailers, COOD represents the sector's first standalone store format centred specifically on this category.
#beauty
According to a translated version of the Yonhap News Agency report, the inaugural outlet will open on the basement level of the company's Pangyo store on 18 September.
Spanning approximately 165.28m², the store will stock more than 60 derma beauty brands.
Derma beauty, a term combining "dermatology" and "beauty", describes products created through research and development involving input from medical and bio-science specialists, aimed at enhancing skin function.
Hyundai Department Store noted that although derma beauty items have already been sold within established beauty retailers, COOD represents the sector's first standalone store format centred specifically on this category.
#beauty
8 days ago
LAS VEGAS — From a fry bread pot roast taco created for the Kansas City Chiefs' visit to A5 Wagyu tomahawks and caviar service in premium areas, Allegiant Stadium is expanding its food and beverage lineup for the 2026 Las Vegas Raiders season.
Silver & Black Hospitality, the stadium's culinary and hospitality provider, unveiled a collection of new concessions, opponent-themed dishes, specialty ***** tails, desserts and premium offerings Tuesday. The additions follow Allegiant Stadium's second-place finishes in nationwide voting for both the AFC's Best NFL Stadium and Best NFL Stadium Food in the 2026 USA TODAY 10 Best Readers' Choice Awards.
"This year we have a lot of new and kind of fun items that we're showcasing and just continuing to elevate our food and beverage program," said Dillon Schoell, senior executive chef at Allegiant Stadium.
New featured concession items include a Fry Bread Pot Roast Taco topped with lettuce, tomato, queso fresco, salsa verde and chipotle crema; a Street Dog Torta with a Sabrett hot dog, pork belly, refried beans and avocado aioli; and a Chile Relleno Burger topped with avocado and crema. The lineup also includes a Focaccia and Lox Sandwich and Really Big Chicken & Waffles served with pickles, hot honey and chives.
Other new items available throughout the season include Buffalo Chicken Wontons, Potato Tacos, an XL Chicken Club Sandwich and a Korean Philly Cheesesteak made with shaved beef, kimchi, mozzarella, provolone, green onions and gochujang aioli.
#items
Silver & Black Hospitality, the stadium's culinary and hospitality provider, unveiled a collection of new concessions, opponent-themed dishes, specialty ***** tails, desserts and premium offerings Tuesday. The additions follow Allegiant Stadium's second-place finishes in nationwide voting for both the AFC's Best NFL Stadium and Best NFL Stadium Food in the 2026 USA TODAY 10 Best Readers' Choice Awards.
"This year we have a lot of new and kind of fun items that we're showcasing and just continuing to elevate our food and beverage program," said Dillon Schoell, senior executive chef at Allegiant Stadium.
New featured concession items include a Fry Bread Pot Roast Taco topped with lettuce, tomato, queso fresco, salsa verde and chipotle crema; a Street Dog Torta with a Sabrett hot dog, pork belly, refried beans and avocado aioli; and a Chile Relleno Burger topped with avocado and crema. The lineup also includes a Focaccia and Lox Sandwich and Really Big Chicken & Waffles served with pickles, hot honey and chives.
Other new items available throughout the season include Buffalo Chicken Wontons, Potato Tacos, an XL Chicken Club Sandwich and a Korean Philly Cheesesteak made with shaved beef, kimchi, mozzarella, provolone, green onions and gochujang aioli.
#items
9 days ago
Healthcare investors looking for long-term growth don't always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-quality companies that are growing for entirely different reasons. Johnson & Johnson (NYSE:JNJ) continues to benefit from the breadth of its pharmaceutical and medical technology businesses, while Thermo Fisher's (NYSE:TMO) outlook increasingly depends on a recovery in life sciences spending after several difficult years.
Both companies reported encouraging results, but does steady diversification or an improving industry cycle offer the stronger long-term opportunity for investors? Let's take a look.
Johnson & Johnson's (NYSE:JNJ) pharmaceutical business was arguably the biggest contributor to its strong quarter, as it helped increase total sales, generating $16.38 billion in quarterly sales and exceeding **** ysts' estimate of $16.1 billion. The healthcare giant now expects its annual sales to be around $101.1 billion at the midpoint, compared with $100.8 billion previously. In another optimistic feat, it raised its adjusted earnings per share forecast to $11.68 at the midpoint, from a previous $11.55 per share.
The most impressive aspect for Johnson & Johnson (NYSE:JNJ), however, wasn't simply pharmaceutical growth but rather the company's ability to offset one of the largest patent cliffs in its portfolio, as it absorbed a significant patent-related decline in Stelara sales while still raising its full-year outlook. Revenue from Johnson & Johnson's (NYSE:JNJ) Stelara, which treats psoriasis, Crohn's disease, and other autoimmune conditions, dropped over 55% in the quarter to $740 million due to patent loss.
However, the company's cancer and newer immunology drugs can be seen countering this loss, as sales of Tremfya, its psoriasis and inflammatory bowel disease drug, rose 72.5% to $2 billion, considerably exceeding the estimate of $1.74 billion. Strong performance from newer drugs such as Tremfya suggests the company's pipeline is successfully offsetting losses from older products.
#billion #tremfya
Both companies reported encouraging results, but does steady diversification or an improving industry cycle offer the stronger long-term opportunity for investors? Let's take a look.
Johnson & Johnson's (NYSE:JNJ) pharmaceutical business was arguably the biggest contributor to its strong quarter, as it helped increase total sales, generating $16.38 billion in quarterly sales and exceeding **** ysts' estimate of $16.1 billion. The healthcare giant now expects its annual sales to be around $101.1 billion at the midpoint, compared with $100.8 billion previously. In another optimistic feat, it raised its adjusted earnings per share forecast to $11.68 at the midpoint, from a previous $11.55 per share.
The most impressive aspect for Johnson & Johnson (NYSE:JNJ), however, wasn't simply pharmaceutical growth but rather the company's ability to offset one of the largest patent cliffs in its portfolio, as it absorbed a significant patent-related decline in Stelara sales while still raising its full-year outlook. Revenue from Johnson & Johnson's (NYSE:JNJ) Stelara, which treats psoriasis, Crohn's disease, and other autoimmune conditions, dropped over 55% in the quarter to $740 million due to patent loss.
However, the company's cancer and newer immunology drugs can be seen countering this loss, as sales of Tremfya, its psoriasis and inflammatory bowel disease drug, rose 72.5% to $2 billion, considerably exceeding the estimate of $1.74 billion. Strong performance from newer drugs such as Tremfya suggests the company's pipeline is successfully offsetting losses from older products.
#billion #tremfya
9 days ago
THUN, Switzerland (AP) — Swiss champion Thun sold two more players Monday from its surprise ******* le-winning team in a tough start to the season that included a quick exit from the Champions League.
Thun said defender Michael Heule joined Heidenheim in Germany and midfielder Valmir Matoshi went to Sturm Graz, the Austrian club that is in the Europa league this season.
Thun reportedly will receive 3.75 million euros ($4.4 million) in combined transfer fees for the pair, who each played more than 30 league games last season as the newly promoted team stunningly eased to its first Swiss ******* le.
In the first home game of its ******* le defense, Thun lost 6-0 to Young Boys and it was 7-0 to Lech Poznan last week in the first leg of a Europa League qualifying playoff. If Thun is eliminated after the return game Thursday it will play in the third-tier Conference League starting Oct. 15.
Thun began its season in Champions League qualifying rounds in July but was eliminated by Dinamo Zagreb. Thun held a two-goal lead deep into the second leg before defender Marco Bürki was sent off.
#thun #team
Thun said defender Michael Heule joined Heidenheim in Germany and midfielder Valmir Matoshi went to Sturm Graz, the Austrian club that is in the Europa league this season.
Thun reportedly will receive 3.75 million euros ($4.4 million) in combined transfer fees for the pair, who each played more than 30 league games last season as the newly promoted team stunningly eased to its first Swiss ******* le.
In the first home game of its ******* le defense, Thun lost 6-0 to Young Boys and it was 7-0 to Lech Poznan last week in the first leg of a Europa League qualifying playoff. If Thun is eliminated after the return game Thursday it will play in the third-tier Conference League starting Oct. 15.
Thun began its season in Champions League qualifying rounds in July but was eliminated by Dinamo Zagreb. Thun held a two-goal lead deep into the second leg before defender Marco Bürki was sent off.
#thun #team
10 days ago
Aug. 24 (UPI) -- Oscar-nominated actor Antonio Banderas will be honored at the 2026 Premios Juventud.
Banderas, 66, known for Desperado, The Mask of Zorro, Pain and Glory and other films, will receive the Agent of Change award for his "impact on education, social action, and community development," according to a press release.
The actor's charity work includes establishing the Lagrimas y Favores Foundation in Malaga, Spain, which benefits the University of Malaga, CUDECA, AECC, Caritas, Fundacion El Pimpi, Economato Social Corinto and other organizations.
In addition, Banderas co-hosts the annual Starlite Gala fundraiser for the Starlite Foundation in Marbella, Spain, alongside Sandra Garcia-Sanjuan.
Antonio Banderas attends the Venice Film Festival photocall for "Babygirl" in 2024. File Photo by Rune ***** estad/UPI
#starlite
Banderas, 66, known for Desperado, The Mask of Zorro, Pain and Glory and other films, will receive the Agent of Change award for his "impact on education, social action, and community development," according to a press release.
The actor's charity work includes establishing the Lagrimas y Favores Foundation in Malaga, Spain, which benefits the University of Malaga, CUDECA, AECC, Caritas, Fundacion El Pimpi, Economato Social Corinto and other organizations.
In addition, Banderas co-hosts the annual Starlite Gala fundraiser for the Starlite Foundation in Marbella, Spain, alongside Sandra Garcia-Sanjuan.
Antonio Banderas attends the Venice Film Festival photocall for "Babygirl" in 2024. File Photo by Rune ***** estad/UPI
#starlite
12 days ago
On August 13, Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter results that captured a company scaling a genuinely new kind of medicine while working through the ***** ps that come with it. ZEVASKYN, its cell therapy for a severe skin disease called recessive dystrophic epidermolysis bullosa, brought in $11.4 million in revenue for the quarter, and the number of patients treated kept rising. But the call also laid out cancellations, manufacturing hiccups, and a shift in how the company plans to report its own progress, all within the same three months.
Revenue climbed 31%, or $2.7 million, to $11.4 million from $8.7 million in the first quarter of 2026. Abeona has now treated 12 patients since ZEVASKYN's launch, including five in the second quarter and three more in the third quarter to date. The treatment center network grew alongside that, reaching seven activated sites with the recent addition of Cincinnati Children's, one of the largest epidermolysis bullosa treatment hubs in the country. New York-Presbyterian/Columbia University Irving Medical Center and Children's Hospital of Philadelphia also came online during the quarter, and CHOP moved fast, completing its first treatment in July just months after activating in May. UTMB, meanwhile, finished its first patient biopsy. Roughly 40% of the addressable patient population now has in-state access to a qualified treatment center.
Abeona also picked up a new technology add-on payment from the Centers for Medicare and Medicaid Services, effective Oct. 1, 2026, for fiscal year 2027, making it one of only three approvals out of 15 new applications that cycle. On the cost side, R&D spending fell to $5 million from $9.6 million, which had included a one-time $7 million licensing payment, and SG&A dropped to $15.8 million from $19.5 million. The company closed the quarter with $146.8 million in cash and short-term investments.
The net loss widened to $20.2 million, or $0.35 per share, from $17.1 million, or $0.30 per share, in the first quarter. Of the five patients treated in the second quarter, only four generated recognized revenue, because one batch's cell yield came in below the threshold required for recognition. Management pointed to ZEVASKYN's 84-hour shelf life as a core operational challenge, since it forces dermatologists, surgeons, anesthesiologists, and hospital staff to lock in exact dates well ahead of time. That rigidity showed up directly in the numbers: two scheduled biopsies were canceled at the last minute in the second quarter after patients' health unexpectedly declined, and because those slots had been booked so far in advance, they could not be filled by another patient.
#abeona #first #center
Revenue climbed 31%, or $2.7 million, to $11.4 million from $8.7 million in the first quarter of 2026. Abeona has now treated 12 patients since ZEVASKYN's launch, including five in the second quarter and three more in the third quarter to date. The treatment center network grew alongside that, reaching seven activated sites with the recent addition of Cincinnati Children's, one of the largest epidermolysis bullosa treatment hubs in the country. New York-Presbyterian/Columbia University Irving Medical Center and Children's Hospital of Philadelphia also came online during the quarter, and CHOP moved fast, completing its first treatment in July just months after activating in May. UTMB, meanwhile, finished its first patient biopsy. Roughly 40% of the addressable patient population now has in-state access to a qualified treatment center.
Abeona also picked up a new technology add-on payment from the Centers for Medicare and Medicaid Services, effective Oct. 1, 2026, for fiscal year 2027, making it one of only three approvals out of 15 new applications that cycle. On the cost side, R&D spending fell to $5 million from $9.6 million, which had included a one-time $7 million licensing payment, and SG&A dropped to $15.8 million from $19.5 million. The company closed the quarter with $146.8 million in cash and short-term investments.
The net loss widened to $20.2 million, or $0.35 per share, from $17.1 million, or $0.30 per share, in the first quarter. Of the five patients treated in the second quarter, only four generated recognized revenue, because one batch's cell yield came in below the threshold required for recognition. Management pointed to ZEVASKYN's 84-hour shelf life as a core operational challenge, since it forces dermatologists, surgeons, anesthesiologists, and hospital staff to lock in exact dates well ahead of time. That rigidity showed up directly in the numbers: two scheduled biopsies were canceled at the last minute in the second quarter after patients' health unexpectedly declined, and because those slots had been booked so far in advance, they could not be filled by another patient.
#abeona #first #center
13 days ago
Socialist Nithya Raman drew loud groans and hisses from a crowd of Democrats during the Los Angeles mayoral debate after she fumbled while explaining her decision to hire the political consulting firm behind disgraced former Senate candidate Graham Platner's campaign.
After winning the Democratic primary for U.S. Senate in Maine, Platner, also a socialist, dropped out of the race in July after several ****** ual misconduct allegations. Even before the allegations arose, Platner had stirred significant controversy over his history of inflammatory statements and a chest tattoo critics say resembles a well-known ****** symbol. Though he continues to deny the ****** ual misconduct allegations and maintains his innocence, Platner remains an embarrassment for many Democrats after several prominent figures in the party endorsed and praised him.
During the debate Wednesday night, Raman, a Los Angeles City Council member and a member of the Democratic Socialists of America (DSA) Los Angeles chapter, faced questions over her decision to hire the consulting firm Fight Agency.
"[It was] reported that you've hired the same political consulting firm that managed Graham Platner's campaign in Maine, who had to resign amidst ****** ual ****** ault allegations. Is that true? And is that the best choice? And why did you make that decision?" the moderator asked.
Karen Bass Ripped After Viral Video Lays Out Taxpayer-funded Match Of Campaign Donations
#raman
After winning the Democratic primary for U.S. Senate in Maine, Platner, also a socialist, dropped out of the race in July after several ****** ual misconduct allegations. Even before the allegations arose, Platner had stirred significant controversy over his history of inflammatory statements and a chest tattoo critics say resembles a well-known ****** symbol. Though he continues to deny the ****** ual misconduct allegations and maintains his innocence, Platner remains an embarrassment for many Democrats after several prominent figures in the party endorsed and praised him.
During the debate Wednesday night, Raman, a Los Angeles City Council member and a member of the Democratic Socialists of America (DSA) Los Angeles chapter, faced questions over her decision to hire the consulting firm Fight Agency.
"[It was] reported that you've hired the same political consulting firm that managed Graham Platner's campaign in Maine, who had to resign amidst ****** ual ****** ault allegations. Is that true? And is that the best choice? And why did you make that decision?" the moderator asked.
Karen Bass Ripped After Viral Video Lays Out Taxpayer-funded Match Of Campaign Donations
#raman
13 days ago
Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum.
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#year #short
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#year #short
13 days ago
Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum.
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#syre #technical #short #valued
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#syre #technical #short #valued
15 days ago
On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company's oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. That kind of breadth from a single-asset biotech is either a sign of real conviction in the science or a company spreading itself thin before it has proven anything. The quarter's numbers and trial updates offer evidence for both readings.
The clearest bright spot is atopic dermatitis. In the highest-dose cohort of a Phase 1 trial, presented at the Society for Investigative Dermatology meeting, 75% of soquelitinib patients hit EASI-75 after 8 weeks of 200 milligram twice-daily dosing, versus 20% of patients on placebo. A quarter of treated patients reached EASI-90, and a third achieved clear or almost-clear skin, outcomes no placebo patient matched. Management also pointed to something more unusual: the benefit persisted after dosing stopped, without the rebound seen with other drugs in the class.
Corvus is carrying that data into a roughly 200-patient Phase 2 trial, called SEERA-1, with enrollment set to finish in early 2027 and results due the following quarter. The company's finances give it room to run. It ended the quarter with $215 million in cash and marketable securities, up from $56.8 million at the end of 2025, largely thanks to $189 million raised in a Q1 follow-on offering, enough to fund operations into the second quarter of 2028.
That cash cushion exists because Corvus is spending a lot more than it used to. R&D costs jumped to $16 million in the quarter from $7.9 million a year earlier, and the net loss more than doubled to $18 million from $8 million, driven by higher trial costs and added headcount tied to soquelitinib. The company remains a one-drug story in practice, and its most advanced program, a Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma, will not offer a public readout soon.
An independent committee is expected to run a futility ***** ysis around the first quarter of 2027, with no data released publicly at that time. Much of the atopic dermatitis story outside the US also runs through Angel Pharmaceuticals, a China-based partner in which Corvus just put another $5 million as part of a $13.5 million financing round. That trial's first cohort of 24 patients is not expected to finish enrolling until September, meaning part of the bull case still sits ahead of the company.
#company
The clearest bright spot is atopic dermatitis. In the highest-dose cohort of a Phase 1 trial, presented at the Society for Investigative Dermatology meeting, 75% of soquelitinib patients hit EASI-75 after 8 weeks of 200 milligram twice-daily dosing, versus 20% of patients on placebo. A quarter of treated patients reached EASI-90, and a third achieved clear or almost-clear skin, outcomes no placebo patient matched. Management also pointed to something more unusual: the benefit persisted after dosing stopped, without the rebound seen with other drugs in the class.
Corvus is carrying that data into a roughly 200-patient Phase 2 trial, called SEERA-1, with enrollment set to finish in early 2027 and results due the following quarter. The company's finances give it room to run. It ended the quarter with $215 million in cash and marketable securities, up from $56.8 million at the end of 2025, largely thanks to $189 million raised in a Q1 follow-on offering, enough to fund operations into the second quarter of 2028.
That cash cushion exists because Corvus is spending a lot more than it used to. R&D costs jumped to $16 million in the quarter from $7.9 million a year earlier, and the net loss more than doubled to $18 million from $8 million, driven by higher trial costs and added headcount tied to soquelitinib. The company remains a one-drug story in practice, and its most advanced program, a Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma, will not offer a public readout soon.
An independent committee is expected to run a futility ***** ysis around the first quarter of 2027, with no data released publicly at that time. Much of the atopic dermatitis story outside the US also runs through Angel Pharmaceuticals, a China-based partner in which Corvus just put another $5 million as part of a $13.5 million financing round. That trial's first cohort of 24 patients is not expected to finish enrolling until September, meaning part of the bull case still sits ahead of the company.
#company
15 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted AnaptysBio, Inc. (NASDAQ:ANAB) as a newly added position. AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company focusing on immunology therapeutics for autoimmune and inflammatory diseases. On August 14, 2026, AnaptysBio, Inc. (NASDAQ:ANAB) closed at $58.47 per share, reflecting a market capitalization of $1.73 billion. AnaptysBio, Inc. (NASDAQ:ANAB) posted a one-month return of 16.27%, while its shares gained 338.15% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding AnaptysBio, Inc. (NASDAQ:ANAB) in its Q2 2026 investor letter:
"Many of our investments require patience. Rather than a clear near-term catalyst, they offer an advantaged product or management team that can build the business and compound value over time. This quarter, we invested in AnaptysBio, a situation that may not require as much patience.
AnaptysBio, Inc. (NASDAQ:ANAB) is a drug royalty company. In 2014, Tesaro licensed a portfolio of pre-clinical antibodies from AnaptysBio. Tesaro, then a small company with $180M in cash, paid AnaptysBio $17M under an agreement designed for two small companies. The agreement included exclusivity and notification provisions and required Tesaro to seek an "optimal commercial return" for AnaptysBio's drugs, which were still in clinical trials.
#road #company #letter
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted AnaptysBio, Inc. (NASDAQ:ANAB) as a newly added position. AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company focusing on immunology therapeutics for autoimmune and inflammatory diseases. On August 14, 2026, AnaptysBio, Inc. (NASDAQ:ANAB) closed at $58.47 per share, reflecting a market capitalization of $1.73 billion. AnaptysBio, Inc. (NASDAQ:ANAB) posted a one-month return of 16.27%, while its shares gained 338.15% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding AnaptysBio, Inc. (NASDAQ:ANAB) in its Q2 2026 investor letter:
"Many of our investments require patience. Rather than a clear near-term catalyst, they offer an advantaged product or management team that can build the business and compound value over time. This quarter, we invested in AnaptysBio, a situation that may not require as much patience.
AnaptysBio, Inc. (NASDAQ:ANAB) is a drug royalty company. In 2014, Tesaro licensed a portfolio of pre-clinical antibodies from AnaptysBio. Tesaro, then a small company with $180M in cash, paid AnaptysBio $17M under an agreement designed for two small companies. The agreement included exclusivity and notification provisions and required Tesaro to seek an "optimal commercial return" for AnaptysBio's drugs, which were still in clinical trials.
#road #company #letter
15 days ago
Botafogo announces that Franclim Carvalho is no longer the head coach of the first-team football squad. The decision was communicated to the professional this Tuesday (18). **** istants Luís Felipe and Mauro Moderno, fitness coach Fábio Monteiro, and goalkeeping coach Ricardo Matos are also leaving the Club.
Botafogo thanks Franclim and the other professionals for their services and wishes them success in their next challenges.
Rodrigo Bellão, the current head coach of the Under-20 team, will take charge of the team on an interim basis and will lead it in the next fixture, against Cienciano, in the second leg of the CONMEBOL Sudamericana round of 16.
Additionally, Botafogo will put in place a new structure for its permanent coaching staff. Paulo Bonamigo, a professional with extensive experience in Brazilian football who managed Botafogo in 2004, takes over as Technical Coordinator.
Ronaldo Torres, a fitness coach with successful spells in Brazilian football, including Brazilian Championship **** les with Botafogo in 1995 and with Fluminense in 2010, will be responsible for Physical Preparation.
#botafogo #head #Fitness
Botafogo thanks Franclim and the other professionals for their services and wishes them success in their next challenges.
Rodrigo Bellão, the current head coach of the Under-20 team, will take charge of the team on an interim basis and will lead it in the next fixture, against Cienciano, in the second leg of the CONMEBOL Sudamericana round of 16.
Additionally, Botafogo will put in place a new structure for its permanent coaching staff. Paulo Bonamigo, a professional with extensive experience in Brazilian football who managed Botafogo in 2004, takes over as Technical Coordinator.
Ronaldo Torres, a fitness coach with successful spells in Brazilian football, including Brazilian Championship **** les with Botafogo in 1995 and with Fluminense in 2010, will be responsible for Physical Preparation.
#botafogo #head #Fitness
15 days ago
Every so often, the six children of Jerry Buss that make up the family trust have a public dispute over the Los Angeles Lakers that reminds us how little they see eye-to-eye when it comes to their father's vision for the team he bought in 1979.
The latest instance came Monday when ESPN's Shams Charania reported the Buss siblings agreed to sell their remaining 17.8 percent stake in the Lakers as part of Mark Walters' sale to Joshua Kushner and Bob Iger, effectively removing Jeanie Buss as governor of the team... only for an attorney for Jeanie to write a letter contesting the sell.
"This is just the latest instance of a years-long pattern whereby Joey and Jesse Buss leak false, defamatory and pernicious 'information' to Mr. Charania for the malicious purpose of doing harm to the Los Angeles Lakers so long as Dr. Buss's chosen successor, Jeanie Buss, carries out her father's wishes," the letter read.
In essence, a year after the Buss' sold their majority stake to Walter -- a process many of the siblings were frustrated by and one that allowed Jeanie to remain governor through 2030 -- the siblings have now voted to sell their remaining stake without the blessing of Jeanie. Thus, we're headed for another public family feud.
And can they please spare us this time? I would love nothing more than if the Buss' could settle their differences privately for once.
#jeanie #siblings #public
The latest instance came Monday when ESPN's Shams Charania reported the Buss siblings agreed to sell their remaining 17.8 percent stake in the Lakers as part of Mark Walters' sale to Joshua Kushner and Bob Iger, effectively removing Jeanie Buss as governor of the team... only for an attorney for Jeanie to write a letter contesting the sell.
"This is just the latest instance of a years-long pattern whereby Joey and Jesse Buss leak false, defamatory and pernicious 'information' to Mr. Charania for the malicious purpose of doing harm to the Los Angeles Lakers so long as Dr. Buss's chosen successor, Jeanie Buss, carries out her father's wishes," the letter read.
In essence, a year after the Buss' sold their majority stake to Walter -- a process many of the siblings were frustrated by and one that allowed Jeanie to remain governor through 2030 -- the siblings have now voted to sell their remaining stake without the blessing of Jeanie. Thus, we're headed for another public family feud.
And can they please spare us this time? I would love nothing more than if the Buss' could settle their differences privately for once.
#jeanie #siblings #public
16 days ago
Dealing with injuries up front, the Indianapolis Colts reportedly worked out a few offensive linemen on Monday.
According to Jake Arthur, the Colts have interior offensive lineman Will Hernandez in for a workout, along with offensive tackles D'Ante Smith and Trey Wedig.
Arthur adds that tackles Luke Tenuta and Nolan Rucci are dealing with injuries. Tenuta appears to be the first tackle option off the bench for the Colts, while Rucci, a UDFA, is fighting for a roster spot.
The top tackle options off the bench at the moment are Blake Freeland and Bayron Matos.
A second-round pick in 2018, Hernandez is quite experienced, playing in 104 career games while making 98 starts. He's played both guard positions.
#arthur
According to Jake Arthur, the Colts have interior offensive lineman Will Hernandez in for a workout, along with offensive tackles D'Ante Smith and Trey Wedig.
Arthur adds that tackles Luke Tenuta and Nolan Rucci are dealing with injuries. Tenuta appears to be the first tackle option off the bench for the Colts, while Rucci, a UDFA, is fighting for a roster spot.
The top tackle options off the bench at the moment are Blake Freeland and Bayron Matos.
A second-round pick in 2018, Hernandez is quite experienced, playing in 104 career games while making 98 starts. He's played both guard positions.
#arthur
16 days ago
BEIJING, Aug 18 (Reuters) - China consigned the body of former Premier Zhu Rongji to the flames on Tuesday and lowered the national flag to mourn the no-nonsense reformer who died last week aged 97, as citizens recalled a bygone era and reflected on his complicated legacy.
Security was tight across the city, particularly around Tiananmen Square and the leaders' enclave of Zhongnanhai, the centre of political power, which lie on the route to the Babaoshan crematorium.
President Xi Jinping and the other six members of the Politburo standing committee stood in silence and made three bows before Zhu was cremated at the Beijing cemetery for top officials and national heroes, the official news agency Xinhua said.
Former President Hu Jintao, 83, who has missed a string of recent public events, sent a wreath of condolence for the former second-ranking official, it added.
A COMPLEX LEGACY
#former #China #premier #rongji
Security was tight across the city, particularly around Tiananmen Square and the leaders' enclave of Zhongnanhai, the centre of political power, which lie on the route to the Babaoshan crematorium.
President Xi Jinping and the other six members of the Politburo standing committee stood in silence and made three bows before Zhu was cremated at the Beijing cemetery for top officials and national heroes, the official news agency Xinhua said.
Former President Hu Jintao, 83, who has missed a string of recent public events, sent a wreath of condolence for the former second-ranking official, it added.
A COMPLEX LEGACY
#former #China #premier #rongji
16 days ago
Despite reports that the Buss family has voted to divest itself of its remaining ownership of the Los Angeles Lakers, team governor Jeanie Buss claims she's not going anywhere.
Ramishah Maruf and Matt Egan of CNN report that Buss's attorneys have contacted her siblings — Jim, Johnny, Janie, Joey and Jesse — in the aftermath of that ESPN report.
Apr 19, 2025; Los Angeles, California, USA; Los Angeles Lakers owner Jeanie Buss and husband Jay Mohr attend the game against the Minnesota Timberwolves at Crypto.com Arena. Mandatory Credit: Jayne Kamin-Oncea-Imagn Images Credit: IMAGN IMAGES via Reuters Connect (Reuters)
"On behalf of Jeanie Buss, I demand that your clients make clear publicly that Jeanie Buss is the Controlling Owner of the Los Angeles Lakers and that your clients shall take no action on this supposed 'vote' to sell the 17.8% stake," read the letter from attorney Adam Streisand.
Streisand also reportedly told CNN that the sale was "falsely reported" by ESPN and that "this is just the latest instance of a years-long pattern whereby Joey and Jesse Buss leak false, defamatory and pernicious 'information.'"
#buss #espn #imagn
Ramishah Maruf and Matt Egan of CNN report that Buss's attorneys have contacted her siblings — Jim, Johnny, Janie, Joey and Jesse — in the aftermath of that ESPN report.
Apr 19, 2025; Los Angeles, California, USA; Los Angeles Lakers owner Jeanie Buss and husband Jay Mohr attend the game against the Minnesota Timberwolves at Crypto.com Arena. Mandatory Credit: Jayne Kamin-Oncea-Imagn Images Credit: IMAGN IMAGES via Reuters Connect (Reuters)
"On behalf of Jeanie Buss, I demand that your clients make clear publicly that Jeanie Buss is the Controlling Owner of the Los Angeles Lakers and that your clients shall take no action on this supposed 'vote' to sell the 17.8% stake," read the letter from attorney Adam Streisand.
Streisand also reportedly told CNN that the sale was "falsely reported" by ESPN and that "this is just the latest instance of a years-long pattern whereby Joey and Jesse Buss leak false, defamatory and pernicious 'information.'"
#buss #espn #imagn
16 days ago
The Buss family's attempt to sell its remaining 17.8% stake in the Los Angeles Lakers has hit a snag. Despite reporting that all six Buss siblings had agreed to sell their shares in the team, there is one that is reportedly contesting the sale: Jeanie Buss, the eldest Buss daughter and the CEO and governor of the team.
In a letter obtained by multiple outlets, Buss' lawyer Adam Streisand wrote that she was opposed to selling the team, and that "any 'vote' by any of the Buss siblings would be and is void" given that it would violate requirements of the Buss's trust, which owns the shares of the Lakers.
A statement attributed to the Buss family earlier on Monday indicated that they had decided to sell the remaining minority ownership of the team to Bob Iger and Josh Kushner as part of the larger sale of the team. A group led by Iger and Kushner agreed to purchase the team from Mark Walter last week, just one year after Walter bought the majority stake from the Buss family.
In the letter, which was posted in full by CNBC, Streisand wrote to three law firms representing Jeanie's siblings — Jim, Johnny, Janie, Joey and Jesse — and urged them to walk back the deal.
Streisand accused ESPN's Shams Charania of "falsely" reporting that all six of the Buss siblings had voted to sell the stake, and accused Joey and Jesse Buss of "leak(ing) false, defamatory and pernicious 'information'" to Charania "for the malicious purpose of doing harm" to the Lakers' organization.
#buss #team #walter
In a letter obtained by multiple outlets, Buss' lawyer Adam Streisand wrote that she was opposed to selling the team, and that "any 'vote' by any of the Buss siblings would be and is void" given that it would violate requirements of the Buss's trust, which owns the shares of the Lakers.
A statement attributed to the Buss family earlier on Monday indicated that they had decided to sell the remaining minority ownership of the team to Bob Iger and Josh Kushner as part of the larger sale of the team. A group led by Iger and Kushner agreed to purchase the team from Mark Walter last week, just one year after Walter bought the majority stake from the Buss family.
In the letter, which was posted in full by CNBC, Streisand wrote to three law firms representing Jeanie's siblings — Jim, Johnny, Janie, Joey and Jesse — and urged them to walk back the deal.
Streisand accused ESPN's Shams Charania of "falsely" reporting that all six of the Buss siblings had voted to sell the stake, and accused Joey and Jesse Buss of "leak(ing) false, defamatory and pernicious 'information'" to Charania "for the malicious purpose of doing harm" to the Lakers' organization.
#buss #team #walter
16 days ago
It's safe to say Paul Hollywood grew up on staple English foods like sticky toffee pudding, Scotch eggs, jam roly-poly, and beans on toast. And while Americans may think barbecue-less beans with a light tomato-based sauce piled on toast sounds just plain weird, many Brits are similarly perplexed by the idea of a peanut ****** er and jelly sandwich. Hollywood is one such Brit who used to think PB&J seemed like an unusual pairing — until he tried it, that is.
The renowned baker and television personality told Mashed that, while he had been curious about peanut ****** er and jelly sandwiches, having heard about them in movies, he didn't grow up with them and remained skeptical. "I was always like, 'What are you crazy? That doesn't go together,'" he said. He'd had both spreads separately before but only had them together when someone on "The Great British Bake Off" made him a peanut ****** er and jelly sandwich. Hollywood didn't fall in love with the sandwich but dubbed it "all right." At least he can now see the appeal of the beloved sweet-and-savory combination. Perhaps he'd be more fond of Ina Garten's elevated PB&J.
Read more: 10 Nostalgic Sandwich Chains That Are Slowly Being Forgotten
Matthew Ashmore/Shutterstock
So, peanut ****** er and jelly didn't wow Paul Hollywood. But one sandwich the "Bake Off" judge does love is an egg and cress, another traditional British favorite often served with afternoon tea. The simple sando features creamy egg salad and peppery watercress nestled between slices of soft bread. But there's one thing he thinks his favorite sandwich should have in common with the average American first-grader's PB&J. In a short video shared on Facebook, Hollywood declared that he prefers to upgrade tea sandwiches by cutting the crusts of his bread off. The celebrity chef also mentioned that he enjoys a ham and cheese sandwich on a crusty baguette as well as a steak sandwich with rocket (aka arugula) on focaccia bread.
#sandwich #jelly #paul
The renowned baker and television personality told Mashed that, while he had been curious about peanut ****** er and jelly sandwiches, having heard about them in movies, he didn't grow up with them and remained skeptical. "I was always like, 'What are you crazy? That doesn't go together,'" he said. He'd had both spreads separately before but only had them together when someone on "The Great British Bake Off" made him a peanut ****** er and jelly sandwich. Hollywood didn't fall in love with the sandwich but dubbed it "all right." At least he can now see the appeal of the beloved sweet-and-savory combination. Perhaps he'd be more fond of Ina Garten's elevated PB&J.
Read more: 10 Nostalgic Sandwich Chains That Are Slowly Being Forgotten
Matthew Ashmore/Shutterstock
So, peanut ****** er and jelly didn't wow Paul Hollywood. But one sandwich the "Bake Off" judge does love is an egg and cress, another traditional British favorite often served with afternoon tea. The simple sando features creamy egg salad and peppery watercress nestled between slices of soft bread. But there's one thing he thinks his favorite sandwich should have in common with the average American first-grader's PB&J. In a short video shared on Facebook, Hollywood declared that he prefers to upgrade tea sandwiches by cutting the crusts of his bread off. The celebrity chef also mentioned that he enjoys a ham and cheese sandwich on a crusty baguette as well as a steak sandwich with rocket (aka arugula) on focaccia bread.
#sandwich #jelly #paul
16 days ago
On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company's oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. That kind of breadth from a single-asset biotech is either a sign of real conviction in the science or a company spreading itself thin before it has proven anything. The quarter's numbers and trial updates offer evidence for both readings.
The clearest bright spot is atopic dermatitis. In the highest-dose cohort of a Phase 1 trial, presented at the Society for Investigative Dermatology meeting, 75% of soquelitinib patients hit EASI-75 after 8 weeks of 200 milligram twice-daily dosing, versus 20% of patients on placebo. A quarter of treated patients reached EASI-90, and a third achieved clear or almost-clear skin, outcomes no placebo patient matched. Management also pointed to something more unusual: the benefit persisted after dosing stopped, without the rebound seen with other drugs in the class.
Corvus is carrying that data into a roughly 200-patient Phase 2 trial, called SEERA-1, with enrollment set to finish in early 2027 and results due the following quarter. The company's finances give it room to run. It ended the quarter with $215 million in cash and marketable securities, up from $56.8 million at the end of 2025, largely thanks to $189 million raised in a Q1 follow-on offering, enough to fund operations into the second quarter of 2028.
That cash cushion exists because Corvus is spending a lot more than it used to. R&D costs jumped to $16 million in the quarter from $7.9 million a year earlier, and the net loss more than doubled to $18 million from $8 million, driven by higher trial costs and added headcount tied to soquelitinib. The company remains a one-drug story in practice, and its most advanced program, a Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma, will not offer a public readout soon.
An independent committee is expected to run a futility ******* ysis around the first quarter of 2027, with no data released publicly at that time. Much of the atopic dermatitis story outside the US also runs through Angel Pharmaceuticals, a China-based partner in which Corvus just put another $5 million as part of a $13.5 million financing round. That trial's first cohort of 24 patients is not expected to finish enrolling until September, meaning part of the bull case still sits ahead of the company.
#corvus #company #pharmaceuticals
The clearest bright spot is atopic dermatitis. In the highest-dose cohort of a Phase 1 trial, presented at the Society for Investigative Dermatology meeting, 75% of soquelitinib patients hit EASI-75 after 8 weeks of 200 milligram twice-daily dosing, versus 20% of patients on placebo. A quarter of treated patients reached EASI-90, and a third achieved clear or almost-clear skin, outcomes no placebo patient matched. Management also pointed to something more unusual: the benefit persisted after dosing stopped, without the rebound seen with other drugs in the class.
Corvus is carrying that data into a roughly 200-patient Phase 2 trial, called SEERA-1, with enrollment set to finish in early 2027 and results due the following quarter. The company's finances give it room to run. It ended the quarter with $215 million in cash and marketable securities, up from $56.8 million at the end of 2025, largely thanks to $189 million raised in a Q1 follow-on offering, enough to fund operations into the second quarter of 2028.
That cash cushion exists because Corvus is spending a lot more than it used to. R&D costs jumped to $16 million in the quarter from $7.9 million a year earlier, and the net loss more than doubled to $18 million from $8 million, driven by higher trial costs and added headcount tied to soquelitinib. The company remains a one-drug story in practice, and its most advanced program, a Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma, will not offer a public readout soon.
An independent committee is expected to run a futility ******* ysis around the first quarter of 2027, with no data released publicly at that time. Much of the atopic dermatitis story outside the US also runs through Angel Pharmaceuticals, a China-based partner in which Corvus just put another $5 million as part of a $13.5 million financing round. That trial's first cohort of 24 patients is not expected to finish enrolling until September, meaning part of the bull case still sits ahead of the company.
#corvus #company #pharmaceuticals
16 days ago
There was plenty to be positive about for Hearts fans after their 6-2 win over Inverness Caledonian Thistle.
New signings got a chance to stake a claim and plenty delivered, with Ugandan winger Rogers Mato and French midfielder Tom Renaud impressing.
But one of the best showings came from a player who was already at the club last season. Well, for half of it anyway.
After returning from a loan spell at Tottenham Hotspur, where he made no first-team appearances after joining in January, James Wilson looks to have a future at Hearts.
But where does the 19-year-old striker fit in Wouter Vrancken's plans?
#plenty
New signings got a chance to stake a claim and plenty delivered, with Ugandan winger Rogers Mato and French midfielder Tom Renaud impressing.
But one of the best showings came from a player who was already at the club last season. Well, for half of it anyway.
After returning from a loan spell at Tottenham Hotspur, where he made no first-team appearances after joining in January, James Wilson looks to have a future at Hearts.
But where does the 19-year-old striker fit in Wouter Vrancken's plans?
#plenty
17 days ago
A strong previous week for two-start pitchers is followed up by a weak group for the current scoring period. A pair of Cardinals headline the list, but once we get past that point, the options mostly include subpar pitchers with favorable matchups.
On the hitting side, a five-game series at Great American Ball Park could provide fireworks.
Kyle Leahy, Cardinals, 39% (@ CIN, @ PHI): The Cardinals tend to save this column during down weeks, as their rotation ranks ninth in baseball in ERA despite lacking a member who is rostered in 50% of Yahoo leagues. After a slow start in his first season as a rotation member, Leahy has been the team's most consistent starter of late, having logged a 1.52 ERA, 0.99 WHIP and 46:9 K:BB ratio in his past nine starts. Although he has been more effective at home (2.91 ERA) than on the road (3.96 ERA), he should have success in two road starts against the Phillies and Reds, who rank 16th and 29th respectively in OPS vs. righties.
Andre Pallante, Cardinals, 38% (@ CIN, @ PHI): Although Leahy has been the Cardinals most reliable starter this summer, Pallante is the rotation member who has been the most consistent throughout the season (3.46 ERA, 1.22 WHIP). The righty lacks the strikeout skills to be a high-end fantasy contributor but maintains a significant floor thanks to his elite groundball rate (55.6%). In a poor week for two-start pitchers, he can be started in any format.
Tyler Mahle, Braves, 30% (@ MIN, @ MIL): Mahle has been terrific across two starts as a member of the Braves, posting a 16:2 K:BB ratio, along with a 0.75 ERA and 0.75 WHIP. But we can't overlook the fact that his 18 outings with the Giants resulted in a 5.13 ERA and 1.39 WHIP. It's worth noting that the ERA estimators don't mind Mahle, ******* igning him marks in the range of 4.00 this season. The right-hander is set to tangle with two top 10 offenses in terms of OPS versus righties, but his success with Atlanta should still get him a look in 12-team leagues.
#member #mahle #rotation
On the hitting side, a five-game series at Great American Ball Park could provide fireworks.
Kyle Leahy, Cardinals, 39% (@ CIN, @ PHI): The Cardinals tend to save this column during down weeks, as their rotation ranks ninth in baseball in ERA despite lacking a member who is rostered in 50% of Yahoo leagues. After a slow start in his first season as a rotation member, Leahy has been the team's most consistent starter of late, having logged a 1.52 ERA, 0.99 WHIP and 46:9 K:BB ratio in his past nine starts. Although he has been more effective at home (2.91 ERA) than on the road (3.96 ERA), he should have success in two road starts against the Phillies and Reds, who rank 16th and 29th respectively in OPS vs. righties.
Andre Pallante, Cardinals, 38% (@ CIN, @ PHI): Although Leahy has been the Cardinals most reliable starter this summer, Pallante is the rotation member who has been the most consistent throughout the season (3.46 ERA, 1.22 WHIP). The righty lacks the strikeout skills to be a high-end fantasy contributor but maintains a significant floor thanks to his elite groundball rate (55.6%). In a poor week for two-start pitchers, he can be started in any format.
Tyler Mahle, Braves, 30% (@ MIN, @ MIL): Mahle has been terrific across two starts as a member of the Braves, posting a 16:2 K:BB ratio, along with a 0.75 ERA and 0.75 WHIP. But we can't overlook the fact that his 18 outings with the Giants resulted in a 5.13 ERA and 1.39 WHIP. It's worth noting that the ERA estimators don't mind Mahle, ******* igning him marks in the range of 4.00 this season. The right-hander is set to tangle with two top 10 offenses in terms of OPS versus righties, but his success with Atlanta should still get him a look in 12-team leagues.
#member #mahle #rotation
18 days ago
KABUL, Afghanistan (AP) — In the hills above Kabul, Sima searches for things that others have left behind. She walks through cemeteries looking for plastic, scrap and anything else that might have value. What can be sold is gathered and carried away; some of what cannot is brought home and saved as fuel for cooking or winter.
Five years after the Taliban returned to power in Afghanistan in August 2021, work is scarce. Sima, who believes she is about 60 but does not know her exact age, helps support her extended family. They survive largely through begging and collecting bread, scrap and recyclable waste.
Little is allowed to go to waste. Bread received from bakeries or other people can be resold cheaply to neighbors. Dry bread collected from the ground is saved and sold to livestock owners. Damaged tomatoes are dried for later, watermelon rinds become torshi, a homemade pickle, and meat received during Eid al-Adha is dried and stored for winter.
These small economies carry risks. Begging and collecting waste have been prohibited by the Taliban, and those caught can be detained. For women such as Sima, finding ways to support their families means navigating an increasingly restricted public life as well as severe poverty. Sima sometimes waits until night to beg, when she feels less exposed on Kabul's streets.
A few months ago, Diba, Sima's daughter, was detained while begging and held for three months. She had a breastfeeding baby at the time, and during her absence the family struggled to provide enough milk and suitable food for the infant. Two days after Diba was released, her baby died.
#bread
Five years after the Taliban returned to power in Afghanistan in August 2021, work is scarce. Sima, who believes she is about 60 but does not know her exact age, helps support her extended family. They survive largely through begging and collecting bread, scrap and recyclable waste.
Little is allowed to go to waste. Bread received from bakeries or other people can be resold cheaply to neighbors. Dry bread collected from the ground is saved and sold to livestock owners. Damaged tomatoes are dried for later, watermelon rinds become torshi, a homemade pickle, and meat received during Eid al-Adha is dried and stored for winter.
These small economies carry risks. Begging and collecting waste have been prohibited by the Taliban, and those caught can be detained. For women such as Sima, finding ways to support their families means navigating an increasingly restricted public life as well as severe poverty. Sima sometimes waits until night to beg, when she feels less exposed on Kabul's streets.
A few months ago, Diba, Sima's daughter, was detained while begging and held for three months. She had a breastfeeding baby at the time, and during her absence the family struggled to provide enough milk and suitable food for the infant. Two days after Diba was released, her baby died.
#bread
